DESIGNED
FOR DECISIONS

Providing molecular diagnostic, prognostic, and therapy guidance insights to support confident clinical decision making in dermatology

EVENTS

Visit us at the AAD Annual Meeting 2026

Stars of the Academy Award Reception

 

 

  • Thursday, March 26 | 4:00-6:00 PM
  • Convention Center Room 601

Resident Networking Reception

 

 

  • Thursday, March 26 | 6:30-9:30 PM
  • Punch Bowl Social

Coffee and
Prizes

Stop by our booth during exhibit hours for a fresh cup of coffee and to spin the wheel to learn more about how our testing can help support clinical decision-making!

  • March 27-29 (Friday-Sunday)
  • Booth #3345
Spots available

Castle Biosciences Social Club

Stop by for sushi, drinks, and discussion. 

  • Friday, March 27 | 7:30-9:30 PM
  • Uchi Denver
RSVP

Skin Cancer,
Take a Hike!

Join us for the 2-mile walk as we increase awareness and protect lives
against skin cancer

 

  • Saturday, March 28 | 6:00-8:00 AM
  • Hyatt Regency Denver

Exhibit
Sip & Social

Join us in booth #3345 for drinks and discussion about our GEP testing.

 

 

  • Saturday, March 28 | 3:00-5:00 PM
  • Booth #3345

Discover the established leader in GEP testing for
dermatologic conditions

300,000+

test reports delivered to healthcare professionals

iStock-1303539296

65+

publications supporting test utilization

View all publications

13,000+

clinicians ordering our testing for their patients

Order a test
COMPREHENSIVE TESTING

Dermatology Test Offerings

PROGNOSTIC

DecisionDx-Melanoma

Delivers personalized insights into a patient’s risk of recurrence and/or metastasis, and likelihood of sentinel lymph node positivity, to guide management decisions for patients with cutaneous melanoma

PROGNOSTIC

DecisionDx-SCC

Provides personalized risk of metastasis and predicts which patients are most likely to benefit from adjuvant radiation therapy, to guide treatment and management decisions for patients diagnosed with squamous cell carcinoma

THERAPY GUIDANCE

AdvanceAD-Tx

Guides systemic treatment decision making in patients with moderate-to-severe atopic dermatitis. 

DIAGNOSTIC

MyPath Melanoma

Guides diagnosis and management decisions, including extent of surgical re-excision and follow-up frequency, for patients with ambiguous melanocytic lesions